ClinicalTrials.gov
ClinicalTrials.gov Menu

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00878293
Recruitment Status : Completed
First Posted : April 8, 2009
Last Update Posted : August 20, 2010
Sponsor:
Information provided by:
Grünenthal GmbH

Brief Summary:
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.

Condition or disease Intervention/treatment Phase
Diabetic Polyneuropathy Drug: GRT6005 Drug: MS Continus® Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy
Study Start Date : April 2009
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Arm Intervention/treatment
Experimental: A
Dose 1, 40 µg
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Experimental: B
Dose 2, 120 µg
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Experimental: C
Dose 3
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Experimental: D
Dose 4
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Experimental: E
Dose 5
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Experimental: F
Dose 6
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Experimental: G
Dose 7
Drug: GRT6005
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Active Comparator: H
Morphin
Drug: MS Continus®
60 mg, capsule, once daily

Placebo Comparator: I
Placebo
Drug: Placebo
liquid formulation and capsule, once daily




Primary Outcome Measures :
  1. Average daily pain intensity [ Time Frame: 5 days ]

Secondary Outcome Measures :
  1. Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values [ Time Frame: 5 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with pain at least NRS >4 due to painful diabetic polyneuropaty.

Exclusion Criteria:

  • Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound planned to be used during the anesthesia, or their excipients.
  • non Caucasian or Hispanic.
  • Concomitant painful disease.
  • Life-long history of seizure disorder or epilepsy.
  • Subjects with clinical relevant cardiac and vascular diseases.
  • Subjects with impaired renal function
  • Subjects with impaired hepatic function
  • Female subjects who are pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00878293


Locations
Germany
Investigator 3
Bad Oeynhausen, Germany
Investigator 1
Mainz, Germany
Investigator 2
Münster, Germany
United Kingdom
Investigator 4
Manchester, United Kingdom
Sponsors and Collaborators
Grünenthal GmbH
Investigators
Principal Investigator: Thomas Forst, Prof. Dr. med IKFE, Parcusstr. 8, 55116 Mainz

Responsible Party: Grünenthal GmbH
ClinicalTrials.gov Identifier: NCT00878293     History of Changes
Other Study ID Numbers: 449723
First Posted: April 8, 2009    Key Record Dates
Last Update Posted: August 20, 2010
Last Verified: August 2010

Keywords provided by Grünenthal GmbH:
analgesic
diabetes mellitus
chronic neuropathic pain
painful polyneuropathy caused by diabetes mellitus type I or II

Additional relevant MeSH terms:
Polyneuropathies
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs